Several brokerages have updated their recommendations and price targets on shares of Akebia Therapeutics (NASDAQ: AKBA) in the last few weeks: 3/16/2016 – Akebia Therapeutics had its price target lowered by analysts at HC Wainwright from $25.00 to $18.00. They now have a “buy” rating on the stock. 3/16/2016 – Akebia Therapeutics had its price […]
